<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H4D11ACF16EB8416788101860C426A701" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 9090 IH: Diane Powis Ovarian Cancer Testing Access Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-09-30</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 9090</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220930">September 30, 2022</action-date><action-desc><sponsor name-id="D000631">Ms. Dean</sponsor> introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to treat certain multimarker testing relating to ovarian cancer as reasonable and necessary for coverage under the Medicare program.</official-title></form><legis-body id="HFD257CE134A344BDA00CFE9BDF9EEFAF" style="OLC"><section id="HD110592157674B7F9630DDB118F166D5" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Diane Powis Ovarian Cancer Testing Access Act</short-title></quote>.</text></section><section id="H6DEEE1DA435F412DBBDCA5048D1F951D"><enum>2.</enum><header>Certain multimarker testing related to ovarian cancer deemed reasonable and necessary for Medicare coverage</header><text display-inline="no-display-inline">Section 1834 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m</external-xref>) is amended by adding at the end the following new subsection:</text><quoted-block style="OLC" id="H1EB06F21313640B28B45475C85074850" display-inline="no-display-inline"><subsection id="H38E11951554847E99BCFB5F334BAB849"><enum>(z)</enum><header>Certain multimarker testing related to ovarian cancer deemed reasonable and necessary</header><paragraph id="H88494043E26F4F939031DACDDCD9C6EE"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">In the case of a clinical diagnostic laboratory test that is a multimarker test related to ovarian cancer that is furnished on or after January 1, 2023, to an individual who has been diagnosed with an ovarian adnexal mass, such test shall be deemed reasonable and necessary for purposes of section 1862(a)(1)(A) if the physician who orders such test determines such test is necessary for such individual and prescribes, dispenses, or administers such test for use in accordance with the labeling approved for such test by the Food and Drug Administration.</text></paragraph><paragraph id="HF8970BC02B204B93821F7090357BCEFB"><enum>(2)</enum><header>Multimarker test related to ovarian cancer defined</header><text>For purposes of this subsection, the term <quote>multimarker test related to ovarian cancer</quote> means a test that evaluates more than one tumor marker with respect to ovarian cancer.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

